This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Swift, P. A Articles by MacGregor, G. A Search for Related Content PubMed PubMed Citation Articles by Swift, P. A Articles by MacGregor, G. A Social Bookmarking                         What's this?

Review: The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations?

Blood Pressure Unit, St. George's Hospital Medical School, London, UK

Graham A MacGregor

Blood Pressure Unit, St. George's Hospital Medical School, London, UK, g.macgregor @sghms.ac.uk

Treatment of high blood pressure (BP) reduces the risk of death and morbidity from stroke and coronary heart disease. There is accumulating evidence from large outcome studies that support a move towards lower treatment targets in hypertensives, particularly for those with concomitant risk factors or evidence of established target organ damage. At present, the achieved rates for BP control in the UK are very poor. Amongst the many possible reasons for poor BP control is the under utilisation of effective drug combinations. This article addresses the rationale for two and three drug combination therapy in hypertension and reviews the trial evidence for efficacy of combinations.

Key Words: hypertension • treatment targets • drug combinations • third-line agents

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 2, 103-108 (2002)
DOI: 10.3317/jraas.2002.010


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?